Jennifer Dotta-Celio
Overview
Explore the profile of Jennifer Dotta-Celio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
28
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bandiera C, Cardoso E, Locatelli I, Zaman K, Diciolla A, Digklia A, et al.
PLoS One
. 2024 Jun;
19(6):e0304573.
PMID: 38848380
Background: Oral anticancer therapies such as protein kinase inhibitors (PKIs) are increasingly prescribed in cancer care. We aimed to evaluate the impact of a pharmacist-led interprofessional medication adherence program (IMAP)...
2.
Bandiera C, Dotta-Celio J, Locatelli I, Nobre D, Wuerzner G, Pruijm M, et al.
Front Pharmacol
. 2024 Feb;
15:1294436.
PMID: 38327981
For every 100 patients with diabetes, 40 will develop diabetic kidney disease (DKD) over time. This diabetes complication may be partly due to poor adherence to their prescribed medications. In...
3.
Bandiera C, Duarte D, Dotta-Celio J, Zanchi A, Schneider M
Rev Med Suisse
. 2023 Jun;
19(829):1085-1089.
PMID: 37260204
Medication non-adherence in patients with diabetic kidney disease (DKD) is endemic. The PANDIA-IRIS study, implemented at the community pharmacy of Unisanté, illustrates the support of medication adherence in patients with...
4.
Bandiera C, Locatelli I, Courlet P, Cardoso E, Zaman K, Stravodimou A, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612312
The cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) palbociclib is administered orally and cyclically, causing medication adherence challenges. We evaluated components of adherence to palbociclib, its relationship with pharmacokinetics (PK), and drug-induced...
5.
Mitropoulou G, Balmpouzis Z, Plojoux J, Dotta-Celio J, Sauty A, Koutsokera A
Respir Med Res
. 2022 Nov;
82:100972.
PMID: 36371896
No abstract available.
6.
Bandiera C, Lam L, Locatelli I, Dotta-Celio J, Duarte D, Wuerzner G, et al.
Diabetol Metab Syndr
. 2022 Sep;
14(1):140.
PMID: 36167584
Background: An interprofessional medication adherence intervention led by pharmacists, combining motivational interviews and feedback with electronic monitor (EM) drug assessment, was offered to all consecutive patients with diabetic kidney disease...
7.
Bandiera C, Pasquier J, Locatelli I, Niquille A, Wuerzner G, Dotta-Celio J, et al.
Patient Prefer Adherence
. 2022 Sep;
16:2313-2320.
PMID: 36046500
Background: During the 2020 COVID-19 lockdown, patients included in the Interprofessional Medication Adherence Program (IMAP) in Switzerland continued to use electronic monitors (EMs) that registered daily drug-dose intake. We aimed...
8.
Bandiera C, Cardoso E, Locatelli I, Digklia A, Zaman K, Diciolla A, et al.
JMIR Res Protoc
. 2021 Jun;
10(6):e30090.
PMID: 34185020
Background: The strengthening or substitution of intravenous cytotoxic chemotherapy cycles by oral targeted anticancer therapies, such as protein kinase inhibitors (PKIs), has provided impressive clinical benefits and autonomy as well...
9.
Bourdin A, Dotta-Celio J, Niquille A, Berger J
Res Social Adm Pharm
. 2021 Jun;
18(4):2706-2710.
PMID: 34154930
Background: Pharmacists played a key role during the coronavirus disease 2019 (COVID-19) pandemic: they contributed to preventing transmission and to maintaining continuity of primary care. Objectives: To present the contributions...
10.
Bandiera C, Dotta-Celio J, Locatelli I, Nobre D, Wuerzner G, Pruijm M, et al.
JMIR Res Protoc
. 2021 Mar;
10(3):e25966.
PMID: 33739292
Background: Despite effective treatments, more than 30% of patients with diabetes will present with diabetic kidney disease (DKD) at some point. Patients with DKD are among the most complex as...